Small Data

Today, Sonos announced that Legrand will be licensing Sonos's patents for manufacturing its NUVO multi-room wireless audio products going forward

price target raised to $58 from $33 at Mizuho price target raised to $45 from $35 at Piper Sandler price target raised to $65 from $46 at BMO Capital price target raised to $37 from $32 at H.C. Wainwright

the best paper ever)

Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) with Cipla

🔥 Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis

Dec 11 (Reuters) - The U.S. Food and Drug Administration said on Friday it would work rapidly toward finalization and issuance of an emergency use authorization for Pfizer Inc's COVID-19 vaccine. A panel of outside advisers to the FDA on Thursday voted overwhelmingly to endorse emergency use of the vaccine, paving the way for the agency to authorize the shot for a country that has lost more than 285,000 lives to COVID-19. The agency has also notified the U.S. Centers for Disease Control and Prevention and Operation Warp Speed so that they can execute their plans for timely vaccine distribution. (Reporting by Ankur Banerjee in Bengaluru; Editing by Saumyadeb Chakrabarty)

tomorrow 25

🚀🔥Requires reading! Bayer pays Atara bio $ atra an advance of $ 60mil and potentially $ 600 mil + royalties with a percentage of future sales towards its target Mesothelin. They enter into strategic partnerships 🚀🔥 - we are waiting for the opening of 🇷🇺 our session and the US session 🇺🇸. There should be a jerk up 🚀, pumps and gaps with closure are possible.

100 today ,)

RUMORS OF FASTLY $ FSLY ABSORPTION BY CISCO $ CSCO

New target price 300$  Evercore ISI - Square $ SQ rating upgraded to Better Market from Market Average Rocket jump)

G1 Therapeutics, a clinical-stage oncology company, today announced that final overall survival (OS) data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) were consistent with preliminary findings announced last year, and showed that trilaciclib significantly improved median OS for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabine/carboplatin. These data will be presented in a Spotlight Poster Session at the 2020 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 9. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.

conference right now!

(NYSE: FSLY), provider of a global edge cloud platform, announced today that Chief Executive Officer Joshua Bixby and Chief Financial Officer Adriel Lares will participate in fireside chats at the following investor conferences: Needham Virtual Security, Networking, and Communications Conference on Tuesday, November 17, 2020 at 12:00 p.m. PT / 3:00 p.m. ET Credit Suisse 24th Annual Technology Conference on Monday, November 30, 2020 at 9:20 a.m. PT / 12:20 p.m. ET 2020 Wells Fargo TMT Summit on Tuesday, December 1, 2020 at 2:20 p.m. PT / 5:20 p.m. ET Webcasts of these presentations will be available on Fastly’s Investor Relations website.